1-Desamino-8-D-arginine vasopressin (dDAVP, Desmopressin acetate) is a synthetic analogue of the natural antidiuretic hormone arginine vasopressin. Its chemical structure is modified by deamination at the 1-position and substitution of L-arginine with D-arginine at the 8-position, which significantly enhances its antidiuretic potency while markedly reducing its vasopressor activity. This peptide is primarily used as a therapeutic agent. It is a well-established API for the treatment of central diabetes insipidus, nocturnal enuresis (bedwetting), and certain bleeding disorders such as mild hemophilia A and von Willebrand's disease (Type I). It acts as a selective agonist for the V2 vasopressin receptors in the renal collecting ducts, promoting water reabsorption and increasing urine osmolality. For hemostatic purposes, it stimulates the release of von Willebrand factor and factor VIII from endothelial cells. Desmopressin is typically administered via intranasal spray, oral tablets, or subcutaneous injection. Its enhanced metabolic stability and receptor selectivity compared to vasopressin result in a longer duration of action and a more favorable safety profile, with minimal effects on blood pressure.